Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals Ltd. has announced the opening of a pro-rata non-renounceable entitlement offer, allowing eligible shareholders to purchase one new share for every six shares held at an issue price of $0.28 per share. This offer aims to raise approximately $10.8 million before costs, with the funds potentially enhancing the company’s operational capabilities and market position.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of synthetic anti-infectives. The company is known for its innovative approach to treating serious infections, positioning itself as a leader in the market for new-generation antibiotics.
YTD Price Performance: -39.58%
Average Trading Volume: 206,124
Technical Sentiment Signal: Buy
Current Market Cap: A$78.45M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.